Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines.

摘要: Oxaliplatin (Oxa) is a third generation platinum drug currently in clinical use for the treatment against colorectal cancer. Although it has somewhat different spectrum of activity than cisplatin (Cis), too two major limitations, namely problems side-effects and resistance. In this study, combined action from combination Oxa with phytochemicals andrographolide (Andro), epigallocatechin-3-gallate (EGCG), chlorophyllin (Chl), colchicines (Col), curcumin (Cur) paclitaxel (Tax) was evaluated human ovarian cancer cell lines A2780 cisR . The index (CI) used as measure synergism (CI 1). Generally, all combinations showed greater at lower concentration (ED 50 ) higher concentrations 75 ED 90) binary Col Tax highest both lines, when administered 4 h after phytochemical, CI ranging 0.004 to 0.1. other generally before phytochemical. Appropriately sequenced tumor active produces marked synergistic effects resistant well non- may offer means overcoming resistance (Oxa), approved by Food & Drug Administration (FDA) US 2002 cancer, (Cis) analogue which carrier ligand 1,2-diamminocyclohexane (DACH)